Up to 4.79% of Mercator Medical shares in the ABB process with high dividend perspective

The company Anabaza controlled by President Wiesław Żyznowski, and Urszula Żyznowska - Chair of the Supervisory Board and the President’s wife in private life, have initiated the accelerated book-building process for a total of up to 508,000 shares in the company. At the same time, they undertook not to sell any shares until June next year (lock-up for six months). Mercator Medical has also announced that 35% of the net profit for 2020 and 2021 will be allocated to dividends and buy-back of own shares.

“Until now, I have never sold any Mercator Medical shares, and what is more – I have bought its shares on the stock exchange. I have also repeatedly pointed out that my majority stake is not for sale, but have clearly signalled an open attitude to smaller transactions – with a view both to increasing the free float and the funds present in the shareholder structure, which is an important aspect for investors and index committees”, indicates Wiesław Żyznowski, PhD, President of the Management Board of Mercator Medical S.A.

“Mercator Medical is only at the beginning of its development path, it has very good prospects and strong foundations. That is why we will reconcile investments with sharing success with shareholders. We intend to allocate 35% of the profit for 2020 and 2021 to dividends and possible buy-back of own shares. It has always been my opinion that a listed company has an obligation to pay dividends, and in addition, for me as the largest shareholder, this is clearly an important matter”, added President Żyznowski.

He now holds directly and indirectly through the company Anabaza a total of over 7 million shares, which represents a total of over 66% of the share capital and secures over 75% of the total number of votes at the General Assembly. Up to 500,000 shares to be sold by President Żyznowski in the ABB process represent less than 4.72% in the share capital and 3.4% of votes at the GA. The process manager is Ipopema Securities.

In the third quarter of the current year, the Mercator Medical Group recorded revenues which are four times higher than a year ago (604.0 million PLN). The Group also earned EBITDA which is 46 times higher (PLN 390.9 million) and net result which is 500 times higher (PLN 355.8 million). Net cash increased by more than half a billion PLN compared to last year.

“We focus on maximising the generated margins. We are an agile organisation, and our advantage is not only efficiency, but also a unique combination of manufacturing and distribution competencies. We are focusing on markets that ensure profitability and on accelerated geographic expansion in developed countries. Western Europe, North America as well as Australia and Oceania have already accounted for 65% of sales in total”, indicates Witold Kruszewski, CFO of Mercator Medical Group.

In June of this year Mercator Medical advanced to the mWIG40, and since October the company’s securities futures have been traded on the WSE. Since December, the company has also been included in the MSCI Small Caps index. Stock analysts indicate Mercator Medical as a candidate for the Polish WIG20 index in the perspective of subsequent index composition revisions. At the same time, since the beginning of the pandemic, this Krakow-based company has been actively involved in the fight against COVID-19 by donating personal protective equipment from its own portfolio to numerous medical and care facilities. To date, Mercator Medical has already donated 1.6 million examination gloves and 50,000 face masks to 55 different institutions, mainly hospitals, nursing homes, hospices and foundations – including the Foundation for the Development of Nursing (Fundacja Rozwoju Pielęgniarstwa), the Foundation of the Sisters of Saint Dominic (Fundacja Sióstr św. Dominika), as well as to the Police Headquarters, the Material Reserves Agency and the Ministry of Health.